Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | company profile
Sunesis Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile (Global Markets Direct)
- Market: Healthcare and Medical
- Published Date: 01/07/2009
- Report Title: Sunesis Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Table of Contents: View Table of Contents
- Report Type: Company Profile
- Country: Global
- Number of Pages: 19
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. As of December 31, 2008, the Company was advancing voreloxin through Phase II development. Voreloxin is an anticancer quinolone derivative (AQD). As of December 31, 2008, Sunesis was conducting three clinical trials of voreloxin: a Phase II clinical trial (known as the REVEAL-1 trial) in previously untreated elderly patients with acute myeloid leukemia (AML), a Phase Ib/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and a Phase II single agent clinical trial in advanced platinum-resistant ovarian cancer patients. The Company has worldwide development and commercialization rights to voreloxin.More from Reuters »
Sunesis Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company engaged in the discovery, development and marketing of oncology therapeutics for the treatment of solid and hematologic cancers. Voreloxin is the company’s lead oncology product which is developed to act as a single agent for treating platinum-resistant ovarian cancer. The company is headquartered in California, United States
The Sunesis Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.
Sunesis Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company engaged in the discovery, development and marketing of oncology therapeutics for the treatment of solid and hematologic cancers. Voreloxin is the company’s lead oncology product which is developed to act as a single agent for treating platinum-resistant ovarian cancer. The company is headquartered in California, United States
The Sunesis Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
